Evidence map›Paper›PMID 34183269›Full record

Observational studyPrimary care diabetes2021

Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study.

Neda Rajamand Ekberg, Ulrik Bodholdt, Andrei-Mircea Catarig, Sergiu-Bogdan Catrina, Katrine Grau, Cecilia Nagorny Holmberg, Boris Klanger, Søren Tang Knudsen

2 registry-linked trialsOpen access · hybridAbstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Primary care diabetes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03648281. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03648281 completed

SURE DENMARK/SWEDEN: A Multi-centre, Prospective, Non-interventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes

Ran2018Enrolled333Registered outcomes18Posted comparisons0ConditionsDiabetes Mellitus, Type 2Armssemaglutide
Open the trial in the graph
NCT06426446 naunknown statusnot on this mapstarted 2024, after this paper: background citation

Monitoring Patients With Severe Obesity Treated With Wegovy® Using Connected Device: Real-world Data

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2024 to 2025Enrolled80ConditionsObesityArmsWithings Body Comp Pro
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 57 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Real-World Effectiveness and Safety of Escalating Once-Weekly Semaglutide from 0.5 to 1.0 mg in Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Article
  9. Article
  10. Observational
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Neda Rajamand EkbergDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Academic Specialist Centre, Centre for Diabetes, Stockholm, Sweden. Electronic address: Neda.ekberg@ki.se.
Ulrik BodholdtKastrup Doctors, Kastrupvej 326, 1.tv., DK-277 Kastrup, Denmark. Electronic address: ulrik@bodholdt.dk.
Andrei-Mircea CatarigNovo Nordisk A/S, Vandtårnsvej 108-110, DK-2860 Søborg, Denmark. Electronic address: aicg@novonordisk.com.
Sergiu-Bogdan CatrinaDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Academic Specialist Centre, Centre for Diabetes, Stockholm, Sweden. Electronic address: Sergiu-bogdan.catrina@ki.se.
Katrine GrauNovo Nordisk A/S, Vandtårnsvej 108-110, DK-2860 Søborg, Denmark. Electronic address: kgau@novonordisk.com.
Cecilia Nagorny HolmbergNovo Nordisk A/S, Vandtårnsvej 108-110, DK-2860 Søborg, Denmark. Electronic address: ccnh@novonordisk.com.
Boris KlangerLäkarGruppen, Källgatan 10, 722 11 Västerås, Sweden. Electronic address: boris.klanger@ptj.se.
Søren Tang KnudsenSteno Diabetes Center Aarhus (SDCA), Aarhus University Hospital, Aarhus, Denmark. Electronic address: soerknud@rm.dk.
Novo Nordisk (Denmark) · DKKarolinska Institutet · SERoyal Danish Academy – Architecture, Design, Conservation · DKSteno Diabetes Centers · DKSwedish Forest Agency · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsAs part of the SURE programme, SURE Denmark/Sweden aimed to study the real-world use of once-weekly (OW) semaglutide in adults with type 2 diabetes (T2D) in Denmark/Sweden.

methodsSURE Denmark/Sweden was an ∼30-week, prospective, multicentre, open-label, observational study, enrolling adults with T2D and ≥1 documented HbA

resultsOf the 331 patients initiating semaglutide, 282 (85%) completed the study on treatment. For the latter, estimated mean changes [95% confidence interval] in HbA

conclusionsIn routine clinical practice in Denmark/Sweden, use of OW semaglutide was associated with glycaemic and weight-loss benefits in a wide range of adults with T2D, supporting real-world use. CLINICALTRIALS. GOV IDENTIFIER: NCT03648281.

Indexed as

Diabetes Mellitus, Type 2AdultDenmarkGlucagon-Like PeptidesGlycated HemoglobinHumansHypoglycemic AgentsProspective StudiesSemaglutideSwedenTreatment OutcomeGlucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsSemaglutideBody weightGlucagon-like peptide-1 receptor agonistHbA(1c)Real-world evidenceSemaglutideSURE studyType 2 diabetes

Identifiers

PMID34183269
OpenAlexW3175542817

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.